Press Releases

-Primary endpoints of safety, tolerability and effect on CFTR function as measured by sweat chloride-
-Phase 2a proof of mechanism clinical trial to enroll people with the most common mutation of cystic fibrosis, known as F508del-

CAMBRIDGE, Mass., Sep 24, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate

CAMBRIDGE, Mass., Sep 23, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.

CAMBRIDGE, Mass., Sep 22, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that intends to offer, subject to market and other conditions, $375.0 million aggregate principal amount of convertible senior subordinated notes due 2015 in an underwritten public

-17% of people achieved SVR with pegylated-interferon and ribavirin alone in the control arm-
-Safety and tolerability results were consistent with prior Phase 3 studies-
-Completion of rolling New Drug Application submission on track for the fourth quarter 2010-

-Viral cure rates of 92% and 88% with 24 and 48-week regimens, respectively, in people who met certain response criteria-
-Safety and tolerability results were similar to those seen in the Phase 3 ADVANCE study-

-Hepatitis C: Rolling submission of New Drug Application underway; data from second pivotal Phase 3 trial - REALIZE - expected in the third quarter of 2010-
-Cystic Fibrosis: Phase 3 registration program for VX-770 fully enrolled; data expected in first half of 2011-
-Financial: Vertex ends second quarter with cash position of approximately $980 million-

CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Wayne J. Riley, M.D., M.B.A., joined its board of directors as an independent director. The addition of Dr. Riley brings the number of Vertex board members to 10. Dr.

-Majority of patients treated with telaprevir received a 24-week regimen-
-6.9% and 7.7% treatment discontinuation rates due to adverse events in 12- and 8-week telaprevir-based treatment arms -- lower than previous telaprevir trials-
-First Phase 3 trial results for a direct acting antiviral therapy in hepatitis C-

CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S.

-HCV: Rolling submission of New Drug Application for telaprevir expected to begin in summer of 2010; first Phase 3 SVR data expected in second quarter 2010 from ADVANCE trial-
-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of Phase 3 registration program for VX-770; data expected in first half of 2011-
-Pipeline: Multiple ongoing or planned proof-of-concept clinical trials with compounds for rheumatoid arthritis and epilepsy and with novel combination regimens for HCV and CF-
-Financial: Vertex ends first quarter with cash position of approximately $1.1 billion-

-VX-222 was well-tolerated across all four dose groups through three days of dosing, with all adverse events being mild to moderate in severity-
-Greater than 3 log₁₀ reduction in HCV RNA observed across all four VX-222 dose groups-
-Results support previously announced Phase 2 proof-of-concept clinical trial evaluating VX-222 in combination with Vertex's lead HCV protease inhibitor telaprevir-

-56% of prior treatment null responder patients achieved SVR with a 48-week telaprevir-based regimen-
-97% of prior treatment relapsers and 55% of prior treatment partial responders achieved SVR with 24-week or 48-week telaprevir-based regimens-

-51% and 53% SVR rates when telaprevir was dosed in combination with pegylated-interferon and ribavirin in treatment-failure patients, compared to 14% SVR rate with pegylated-interferon and ribavirin alone-
-Telaprevir Phase 3 SVR data expected in second quarter 2010 for treatment-naïve patients and third quarter 2010 for treatment-failure patients-
-New Drug Application submission planned for second half of 2010 in treatment-naïve and treatment-failure HCV patients-

CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th

-Trial will evaluate safety and SVR rates with multiple 12-week response-guided regimens of telaprevir/VX-222-based combination therapy, including two-drug regimens of telaprevir and VX-222-
-Interim clinical data expected in the second half of 2010-
-Multiple clinical trial sites in the U.S. to enroll patients-

CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the

-HCV: New Drug Application planned for telaprevir in second half of 2010; increasing investment in commercialization and launch preparedness activities-
-CF: Development progress with two compounds in orphan disease of cystic fibrosis; combination trial planned with VX-770 and VX-809 based on Phase 2 data for VX-809-
-Pipeline: Proof-of-concept clinical trials planned for 2010 with novel combination regimens for hepatitis C and cystic fibrosis and with compounds for rheumatoid arthritis and epilepsy-
-Financial: Vertex enters 2010 with approximately $1.3 billion in cash, cash equivalents and marketable securities and approximately $32 million in outstanding 2013 convertible debt; 2010 investment to support long-term business objectives-

-VX-809 was well-tolerated at all dose levels when dosed once daily for 28 days-
-Statistically significant changes observed in measurement of sweat chloride suggest increased CFTR activity-
-Data support planned combination trial of VX-809 and VX-770 in second half of 2010 for CF patients with the F508del mutation-

-HCV:New Drug Application planned for telaprevir in second half of 2010, robust commercialization and launch preparedness activities ongoing-
-CF:Advancing development efforts in orphan disease of cystic fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment, VX-809 Phase 2 data expected in first quarter 2010-
-Pipeline:Proof-of-concept clinical trials planned for 2010 with novel combination regimens for hepatitis C and cystic fibrosis and with compounds for rheumatoid arthritis and epilepsy-
-Financial:Vertex enters 2010 with approximately $1.3 billion in cash, cash equivalents & marketable securities and approximately $32 million in outstanding convertible debt-